With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Related to this article
Experts in gynecologic oncology overview top research being presented at the 2026 ESMO Congress.
The estimated 3-year OS rate with botensilimab plus balstilimab was 48% in heavily pretreated recurrent ovarian cancer in the phase 1b C-800-01 trial.
A patient treated at the highest dose level of lira-cel to date had stable disease 90 days after infusion in a phase 1 trial in recurrent ovarian cancer.
Advertisement
Advertisement
Trending on OncLive
1
Lifileucel Linked to Low Rates of Post-Discharge Severe TRAEs, Readmissions in Advanced Melanoma
2
VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer
3
Chronicity of Immune-Related AEs Drives QOL Burden With Adjuvant Checkpoint Inhibition in Resected RCC
4
Sequencing B7-H4–Targeted ADCs and Optimizing Toxicity Management in Gynecologic Cancers
5